ERBB2 and neoplasm: Application of this strategy to doxorubicin-loaded PEGylated (DSPE-PEG2000) liposomes harboring an HER2-specific peptide led to pH-dependent doxorubicin release in vitro and superior tumor growth inhibition than did untargeted vesicles or targeted vesicles devoid of pH-responsiveness [291].